Delcath Systems, Inc. (DCTH) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Delcath Systems, Inc. is an interventional oncology company focused on treating primary and metastatic liver cancers. Its lead product, HEPZATO KIT, is an FDA-approved drug/device combination for uveal melanoma with hepatic metastases. The company also markets the CHEMOSAT hepatic delivery system in Europe. As of July 31, 2025, 34,981,253 shares of common stock were outstanding.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 (3 Months) | YTD 2025 (6 Months) | Q2 2024 (3 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $24,156 | $43,940 | $7,766 | $10,905 |
| Gross Profit | $20,838 | $37,777 | $6,247 | $8,483 |
| Gross Margin | 86.3% | 86.0% | 80.4% | 77.8% |
| Operating Income | $2,590 | $3,232 | ($3,912) | ($14,190) |
| Net Income | $2,697 | $3,766 | ($13,741) | ($24,852) |
| Diluted EPS | $0.07 | $0.09 | ($0.48) | ($0.93) |
| Cash & Equivalents | $34.4M (as of June 30, 2025) | |||
| Short-term Investments | $46.6M (as of June 30, 2025) | |||
| Operating Cash Flow (YTD) | $9.5M provided |
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased 211% year-over-year for the quarter and 303% year-over-year for the six-month period, driven by the commercial expansion of HEPZATO in the U.S. and CHEMOSAT in Europe. The number of facilities treating patients with HEPZATO grew from 7 in the first half of 2024 to 20 in the first half of 2025.
- Profitability Turnaround: The company reported a net profit of $2.7M for Q2 2025, a significant improvement from a net loss of $13.7M in Q2 2024. This shift was driven by revenue growth and the elimination of warrant liability fair value adjustments and interest expenses that impacted the prior year.
- Expense Growth: Operating expenses increased to $18.2M in Q2 2025 from $10.2M in Q2 2024. This increase is attributed to higher R&D costs for new Phase 2 clinical trials and increased SG&A due to commercial expansion and higher stock-based compensation.
- Liquidity Position: Total cash and short-term investments increased from $53.2M at year-end 2024 to $81.0M at June 30, 2025, bolstered by operating cash flow and proceeds from warrant exercises.
Guidance, Outlook, and Risks
- Clinical Pipeline: The company has received FDA clearance for two Phase 2 trials: one for liver-dominant metastatic colorectal cancer (enrollment expected H2 2025) and one for liver-dominant metastatic breast cancer (enrollment expected Q4 2025).
- Regulatory & Pricing: Delcath entered the National Drug Rebate Agreement (NDRA) and Pharmaceutical Pricing Agreement (PPA) effective July 1, 2025, subjecting HEPZATO to 340B pricing and Medicaid rebates. The company is evaluating the impact of the "One Big Beautiful Bill" (OBBB) signed July 4, 2025, which restores immediate expensing of R&D costs.
- Liquidity Outlook: Management believes current cash and investments are sufficient to fund operations for at least 12 months. Capital commitments over the next 12 months include approximately $10.4M for payables, leases, and the medac settlement.
- Risks: Key risks include the complexity of government pricing programs (340B, Medicaid), potential penalties for reporting errors, supply chain disruptions, and the uncertainty of clinical trial outcomes for new indications.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the 211% revenue growth and the mix of consignment vs. direct sales for HEPZATO.
- Government Pricing Impact: Assess the financial impact of the new 340B and Medicaid rebate obligations effective July 2025 on future gross margins.
- Cash Burn vs. Runway: Confirm the $10.4M capital commitment against the $81M liquid asset base to validate the 12-month liquidity runway.
- Clinical Trial Costs: Monitor the acceleration of R&D expenses as the two new Phase 2 trials commence enrollment in late 2025.
- medac Settlement: Review the $0.8M contingent liability related to the medac settlement and its potential cash outflow requirements.